Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. director Ellen G. Cooper filed an initial ownership report on Form 3 stating that she currently holds no securities of Cencora. The filing confirms her status as a director and formally records that she has no beneficial ownership of the company’s securities at this time.
Cencora, Inc. President & CEO Robert P. Mauch reported an option exercise and share sale. On January 20, 2026, he exercised a non-qualified stock option for 3,763 shares of Cencora common stock at an exercise price of $86.09 per share. On the same date, he sold 5,096 shares of common stock at a price of $354.73 per share. After these transactions, he directly owned 66,726 shares of Cencora common stock and held 3,762 stock options linked to common shares. The option referenced in the filing became exercisable in four equal installments from November 13, 2020 through November 13, 2023.
Cencora is asking shareholders to vote at its virtual 2026 annual meeting on March 5, 2026 to elect 11 directors, approve fiscal 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for fiscal 2026. The company reports fiscal 2025 revenue of $321.3 billion and total shareholder return of 40%, and says it returned nearly $900 million through dividends and share repurchases.
Cencora highlights progress on its pharmaceutical‑centric strategy, including acquiring Retina Consultants of America and announcing plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network. Board refresh and governance are central themes: 10 of 11 nominees are independent, eight have joined in the past five years, and D. Mark Durcan became independent Board Chair on October 1, 2025.
The proxy emphasizes board diversity, succession planning, and extensive shareholder engagement on topics such as the CEO transition to Robert P. Mauch, risk oversight, compensation design, and corporate responsibility. It also details committee structures overseeing capital allocation, executive pay, compliance, risk management, and controlled substances distribution.
Cencora, Inc. reported that its Board of Directors appointed Ellen G. Cooper as a director, effective January 20, 2026. To accommodate this change, the Board increased its size from ten to eleven members under the company’s Amended and Restated Bylaws.
Ms. Cooper will receive the same compensation and benefits as other non-employee directors under Cencora’s Compensation Policy for Non-Employee Directors, with all cash and equity amounts pro-rated from her appointment date through the company’s 2026 Annual Meeting of Stockholders. The company states there are no arrangements or understandings with other persons regarding her appointment, no family relationships with existing directors or executive officers, and no related-party transactions requiring disclosure. She has not yet been named to any Board committees.
Cencora also issued a news release on January 22, 2026 announcing the appointment, which is furnished as Exhibit 99.1 to this report.
Form 144 reports a planned insider sale of 5,096 common shares through Fidelity Brokerage Services LLC on the NYSE around 01/20/2026. The planned sale has an aggregate market value of 1,807,704.08 based on the filer’s calculation, compared with 193,993,444 common shares outstanding. The shares to be sold come from 1,333 shares acquired via restricted stock vesting on 11/09/2024 as compensation and 3,763 shares acquired on 01/20/2026 from options originally granted on 11/13/2019 and paid for in cash.
Over the prior three months, Robert Mauch has sold common shares of the same issuer in three transactions: 5,097 shares on 10/20/2025 for gross proceeds of 1,665,699.60, 5,096 shares on 11/18/2025 for 1,868,397.44, and 5,096 shares on 12/18/2025 for 1,750,221.20. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Cencora, Inc. has expanded its financing capacity to support its planned acquisition of OneOncology. The company increased total commitments under its revolving credit facility by $1.0 billion to $5.5 billion, providing additional flexible liquidity.
Cencora also entered into a new senior unsecured term loan agreement totaling $1.5 billion, split into a $500 million tranche maturing two years after draw and a $1.0 billion tranche maturing three years after draw. In addition, the company arranged a separate $3.0 billion 364-day senior unsecured term loan. Proceeds from these loans will help fund the OneOncology purchase price, repay OneOncology’s existing debt, and cover related fees and expenses. Both facilities include leverage covenants generally capped at 4.00 to 1.00, which may temporarily increase to 4.50 to 1.00 when closing a material acquisition, and their funding is conditioned on consummation of the acquisition. These new facilities fully replace previously obtained $4.5 billion bridge financing commitments.
Cencora, Inc. Executive Vice President Silvana Battaglia reported acquiring company shares through an employee stock purchase program. On December 31, 2025, she acquired 27.344 shares of Cencora common stock at a price of $287.088 per share under the Employee Stock Purchase Plan, which is noted as exempt under Rule 16b-3(c) and Rule 16b-3(d). After this purchase, she beneficially owned 18,823.808 shares of common stock in direct ownership.
Cencora, Inc. Executive Vice President Elizabeth S. Campbell reported a small purchase of company common stock. On December 31, 2025, she acquired 33.526 shares of Cencora common stock at a price of $287.088 per share. The filing states this purchase was made through the company’s Employee Stock Purchase Plan under exemptions provided by Rule 16b-3(c) and Rule 16b-3(d). After this transaction, Campbell beneficially owned a total of 23,924.667 shares of Cencora common stock, held in direct ownership.
Cencora, Inc. reported an insider stock sale by an executive vice president on a Form 4. On 12/19/2025, the officer sold 1,677 shares of Cencora common stock at a price of $345 per share, coded as a sale transaction. After this trade, the reporting person beneficially owned 18,796.464 shares of common stock directly. The filing reflects a single non-derivative transaction, with no derivative securities reported.